DETECTION OF HPV TYPE 45 L2 GENE IN CERVICAL CANCER PATIENTS BY POLYMERASE CHAIN REACTION METHOD
Keywords:Cervical cancer, HPV type 45, L2 gene, PCR
Objective: Cervical cancer is the second common type of cancer among women in the Indonesian population. Persistent infection with high risk human papillomavirus (hrHPV) has been considered as the most significant risk factor of cervical cancer. Research on the identification of HPV type 45 L2 gene as the third cause of cervical cancer in Indonesia is still small even has not been done in West Sumatera and Riau, whereas HPV gene identification by molecular biology techniques can be used as an initial screening for cervical cancer.
Methods: DNA was isolated from 43 samples of cervical smears and cervical cancer biopsies obtained from M. Djamil General Hospital, Padang and Arifin Achmad General Hospital, Pekanbaru. HPV DNA detection was conducted using polymerase chain reaction (PCR) using GP5+/6+primers. HPV type 45 L2 gene were identified by PCR method with HPV type 45 L2 genes specific primers.
Results: The concentration of the isolated DNA varied from 2.8 to 326.3 ng/Âµl. Isolates DNA from tissue samples had good value of purity and the purity of isolated DNA from cervical smear samples was not too good, Amplification of HPV DNA showed that 20 tissue samples and 6 cervical smear samples were positive HPV DNA. There was only one sample (Hpv. J.14) which L2 genes of HPV type 45.
Conclusion: Results of DNA amplification by PCR method showed that 60.47% of cervical cancer patients in this study infected with HPV DNA and 3.85% sample had gene L2 of HPV type 45.
Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M. Human papillomavirus and related diseases report in Indonesia. Barcelona: ICO Information Center on HPV and Cancer; 2015.
Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006;24:1-25.
Munoz N, Bosch FX, de Sanjose S. Epidemiologic classification of Human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:8-27.
Guan P, Howell-Jones R, Li N, Bruni L. Human papillomavirus types in 115,789 HPV-positive women, a meta analysis of cervical infection to cancer. Int J Cancer 2012;131:2349-59.
Chan PKS, Picconi MA, Cheung TH, Giovannelli L, Park JS. Laboratory and clinical aspects of human papillomavirus testing. Clin Lab Sci 2012;49:117-36.
Abreu ALP, Souza RP, Gimenes F, Consolaro MEL. A review of methods for detect Human papillomavirusinfection. Virol J 2012;9:262.
Surzycki S. Human molecular biology laboratory. Malden: Black Well Publishing; 2003.
Calladine CR, Drew HP, Luisi BF, Travers AA. Understanding DNA the molecule and how it works. 3rd ed. London: Elsevier; 2004.
Siddiqa A, Zainab M, Qadri I, Bhatti MF, Parish JL. Prevalence and genotyping of high risk Human papillomavirus in cervical cancer samples from Punjab, Pakistan. Viruses 2014;6:2762-77.
Tyler M, Tumban E, Chackerian B. Second-generation prophylactic HPV vaccines: successes and challenges. Vaccines 2014;1:1-9.
Panigoro R, Susanto H, Novel SS, Hartini S, Sahiratmadja E. HPV genotyping linear assay test comparison in cervical cancer patients, implications for HPV Prevalence and molecular epidemiology in a limited-resource area in Bandung, Indonesia. Asian Pac J Cancer Prev 2013;14:5843-47.
Vet JNI, de Boer1 MA, van den Akker B, Siregar B, Lisnawati, Budiningsih S, et al. Prevalence of Human papillomavirus in Indonesia, a population-based study in three regions. Br J Cancer 2008;99:214-8.